Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Lia Gore

Showing results (21-30 of 119) with videos related to

Pageof 12
Sort By:
Pediatric Blood & Cancer|August 1, 2020
Single-center pediatric experience with venetoclax and azacitidine as treatment for myelodysplastic syndrome and acute myeloid leukemiaAmanda C Winters, Kelly W Maloney, Amy L Treece, et al.
Pediatric Blood & Cancer|November 6, 2008
Small cell undifferentiated variant of hepatoblastoma: adverse clinical and molecular features similar to rhabdoid tumorsAngela D Trobaugh-Lotrario, Gail E Tomlinson, Milton J Finegold, et al.
Pediatric Blood & Cancer|April 13, 2006
MGMT promoter methylation correlates with survival benefit and sensitivity to temozolomide in pediatric glioblastomaAndrew M Donson, Steven O Addo-Yobo, Michael H Handler, et al.
The Lancet. Oncology|April 8, 2015
Accepting risk in the acceleration of drug development for rare cancersDavid Ashley, David Thomas, Lia Gore, et al.
British Journal of Haematology|September 4, 2010
Targeting paediatric acute lymphoblastic leukaemia: novel therapies currently in developmentAlisa B Lee-Sherick, Rachel M A Linger, Lia Gore, et al.
Pediatric Blood & Cancer|June 2, 2005
Cord blood transplant in childhood ALLKelly K Sawczyn, Ralph Quinones, Janet Malcolm, et al.
Neuro-Oncology|March 6, 2013
A phase I trial of arsenic trioxide chemoradiotherapy for infiltrating astrocytomas of childhoodKenneth J Cohen, Iris C Gibbs, Paul G Fisher, et al.
Pediatric Blood & Cancer|June 18, 2009
PARP1 expression in pediatric central nervous system tumorsValerie N Barton, Andrew M Donson, B K Kleinschmidt-DeMasters, et al.
Oncotargets and Therapy|September 28, 2011
Systematic in-vitro evaluation of the NCI/NIH Developmental Therapeutics Program Approved Oncology Drug Set for the identification of a candidate drug repertoire for MLL-rearranged leukemiaKimberley A Hoeksema, Aarthi Jayanthan, Todd Cooper, et al.
Blood|July 2, 2002
Runx1 is essential for hematopoietic commitment at the hemangioblast stage of development in vitroGeorges Lacaud, Lia Gore, Marion Kennedy, et al.
Pageof 12

Showing results (21-30 of 119) with videos related to

Sort By:
Pageof 12
Pediatric Blood & Cancer|August 1, 2020
Single-center pediatric experience with venetoclax and azacitidine as treatment for myelodysplastic syndrome and acute myeloid leukemiaAmanda C Winters, Kelly W Maloney, Amy L Treece, et al.
Pediatric Blood & Cancer|November 6, 2008
Small cell undifferentiated variant of hepatoblastoma: adverse clinical and molecular features similar to rhabdoid tumorsAngela D Trobaugh-Lotrario, Gail E Tomlinson, Milton J Finegold, et al.
Pediatric Blood & Cancer|April 13, 2006
MGMT promoter methylation correlates with survival benefit and sensitivity to temozolomide in pediatric glioblastomaAndrew M Donson, Steven O Addo-Yobo, Michael H Handler, et al.
The Lancet. Oncology|April 8, 2015
Accepting risk in the acceleration of drug development for rare cancersDavid Ashley, David Thomas, Lia Gore, et al.
British Journal of Haematology|September 4, 2010
Targeting paediatric acute lymphoblastic leukaemia: novel therapies currently in developmentAlisa B Lee-Sherick, Rachel M A Linger, Lia Gore, et al.
Pediatric Blood & Cancer|June 2, 2005
Cord blood transplant in childhood ALLKelly K Sawczyn, Ralph Quinones, Janet Malcolm, et al.
Neuro-Oncology|March 6, 2013
A phase I trial of arsenic trioxide chemoradiotherapy for infiltrating astrocytomas of childhoodKenneth J Cohen, Iris C Gibbs, Paul G Fisher, et al.
Pediatric Blood & Cancer|June 18, 2009
PARP1 expression in pediatric central nervous system tumorsValerie N Barton, Andrew M Donson, B K Kleinschmidt-DeMasters, et al.
Oncotargets and Therapy|September 28, 2011
Systematic in-vitro evaluation of the NCI/NIH Developmental Therapeutics Program Approved Oncology Drug Set for the identification of a candidate drug repertoire for MLL-rearranged leukemiaKimberley A Hoeksema, Aarthi Jayanthan, Todd Cooper, et al.
Blood|July 2, 2002
Runx1 is essential for hematopoietic commitment at the hemangioblast stage of development in vitroGeorges Lacaud, Lia Gore, Marion Kennedy, et al.
Pageof 12